Dry Eye Syndromes
Conditions
Brief summary
Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease. However, exact information about influence on tear film thickness and corneal residence time of topical lubricants is still sparse, therefore no ideal treatment regimen has been found. Recently a new method for assessment of tear film thickness based on ultra-high resolution optical coherence tomography (OCT) has become available. The aim of the present study is to assess the influence on tear film thickness of three different formulations of topical lubricants, in particular Thealoz Duo® Eye Drops, Optive® Eye Drops and Systane Ultra® Eye Drops in patients with moderate to severe dry eye disease. In addition, standard tests for dry eye syndrome, such as the ocular surface disease index (OSDI©), Schirmer I test, corneal fluorescein staining and determination of tear break up time (BUT) will be performed to compare the product effects.
Interventions
DEVICEThealoz Duo Eye Drops
Manufacturer: Laboratoires Thea, France
DEVICEOptive Eye Drops
Manufacturer: Allergan Pharmaceuticals, Ireland
DEVICESystane Ultra Eye Drops
Manufacturer: Alcon Pharma GmbH
Sponsors
Medical University of Vienna
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men and women aged over 18 years 2. Signed and dated written informed consent 3. History of dry eye syndrome for at least 3 months 4. Tear Break Up Time (BUT) ≤ 10 seconds or Schirmer I test ≤ 5 mm and ≥ 2mm 5. OSDI ≥ 22 6. Normal ophthalmic findings except dry eye syndrome, ametropia \< 6 Dpt. 7. No administration of topical lubricants 24 hours before the screening examination
Exclusion criteria
1. Presence of an ocular pathology judged by the investigator as incompatible with the study. 2. Any other clinical relevant ocular abnormality except DES. 3. History of allergy, known hypersensitivity to one of the components: the study medications or Fluorescein. 4. History of known clinically relevant allergy. 5. Medical or surgical history judged by the investigator to be incompatible with the study participation (hepatic or renal insufficiency; all chronic severe organic disease: metabolic, endocrine, neoplasic, haematological disease; severe psychiatric illness, etc.). 6. History of a recent acute illness with a recovery period within the 2 weeks before the inclusion visit (Day 0). 7. Pregnancy, lactation. 8. Pre-menopausal woman who is not using a reliable birth control method (oral contraceptives or coil) or is not surgically sterilised. 9. Participation in any high-speed or water-sports during the study without ocular protection (goggles or glasses). 10. Subject unable to understand the study instructions or unlikely to comply with the study schedule and treatment. 11. Participation in another clinical study in the 4 weeks before the start of the present study or at the same time as the present study. 12. Subject is a ward of court.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in tear film thickness as measured with Optical Coherence Tomography (OCT) | 10 weeks; at baseline, 10 minutes, 20 minutes, 40 minutes, 60 minutes, 120 minutes and 240 minutes after instillation of eye drops as well as 4 weeks and 8 weeks after the first instillation | Tear film thickness as measured with Optical Coherence Tomography (OCT) predose and at defined time points after the first instillation, as well as on each study day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjective evaluation of ocular comfort with questionnaire | 10 weeks | — |
| Schirmer I test | 10 weeks | — |
| OSDI score | 10 weeks | — |
| Tear Break Up Time (BUT) | 10 weeks | — |
| Conjunctival hyperemia score | 10 weeks | — |
| Efficacy assessment of eye drops by the patient with questionnaire | 10 weeks | Efficacy of eye drops will be performed by the patient by choosing one of the following options: * Very satisfactory * Satisfactory * Not very satisfactory * Unsatisfactory |
| Efficacy assessment of eye drops by the investigator with questionnaire | 10 weeks | Efficacy of eye drops will be performed by the investigator by choosing one of the following options: * Very satisfactory * Satisfactory * Not very satisfactory * Unsatisfactory |
| Corneal fluorescein staining (Oxford grading scale) | 10 weeks | — |
Countries
Austria
Outcome results
None listed